ONCO Prime – A Comprehensive Platform for Identification of KRAS-Specific Synthetic Lethal Targets Using Patient-Derived Cells
Time: 4:45 pm
day: Day One
Details:
• Showcasing Ryvu’s cutting-edge drug discovery platform, uniquely combining high throughput capabilities with the precision and translational impact traditionally associated with later, lower throughput stages
• Leveraging human stem cell-derived model cells (PDC), patient-derived xenografts (PDXs) and clinical samples to create a groundbreaking approach to identify synthetic lethal (SL) targets specific to oncogenic pathways
• In conjunction with our novel ranking algorithm, these models have successfully identified potential drug targets in KRAS-mutant cells—targets that remained undetected in immortalized CRC cell lines, likely due to genetic and epigenetic alterations accumulated over years of cell culture
